key: cord-1001459-x4mgnhbg authors: Stricker, Raphael B.; Fesler, Melissa C. title: Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Workers from India: A Meta-Analysis date: 2021-08-05 journal: J Infect Public Health DOI: 10.1016/j.jiph.2021.08.001 sha: 4901fd8fa0af4ac71d022dbff8feb9951941e9a2 doc_id: 1001459 cord_uid: x4mgnhbg To date, the COVID-19 pandemic has resulted in more than 180 million cases of SARS-CoV-2 infection and more than four million deaths world-wide. 1 Although novel COVID-19 vaccines have become clinically available, the safety and efficacy of these vaccines remains open to question. 2 Alternate approaches to prevention of disease have received little attention, and one medication, hydroxychloroquine (HCQ), has been attacked and dismissed based on flawed studies and political controversy that obscured the value of this treatment as pre-exposure prophylaxis (PrEP) for SARS-CoV-2 infection. To date, the COVID-19 pandemic has resulted in more than 180 million cases of SARS-CoV-2 infection and more than four million deaths world-wide. 1 Although novel COVID-19 vaccines have become clinically available, the safety and efficacy of these vaccines remains open to question. 2 Alternate approaches to prevention of disease have received little attention, and one medication, hydroxychloroquine (HCQ), has been attacked and dismissed based on flawed studies and political controversy that obscured the value of this treatment as pre-exposure prophylaxis (PrEP) for SARS-CoV-2 infection. A British study of 120,075 healthcare workers (HCWs) found that these subjects had a 7-8 fold greater risk of developing severe COVID-19 compared to non-HCWs. 3 With this background, the Indian Council of Medical Research (ICMR) National Taskforce for COVID-19 formulated guidelines for weekly HCQ PrEP in high-risk HCWs. 4 We used internet search engines to identify 11 cohort studies of weekly HCQ PrEP in HCWs from India based on the ICMR protocol. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] These case-control studies enrolled a total of 7,616 high-risk HCWs who were tested for SARS-CoV-2 infection as an endpoint after varying lengths of time following weekly HCQ PrEP or no treatment. We have performed a preliminary meta-analysis of these studies, as shown in Table 1 . In the 11 studies that included HCWs who used any HCQ PrEP, the infection rate was significantly decreased (RR 0.56, p=0.0040). In the five studies that included HCWs who took at least six doses of weekly HCQ PrEP, the infection rate was reduced even further (RR 0.25, p<0.0001). The uniform ICMR treatment protocol used in these studies argues against bias related to variations in dosing of HCQ. There were minimal adverse events reported in the HCQ-treated subjects, consistent with other safety reports for HCQ use in COVID-19 trials. 16, 17 Our meta-analysis suggests that weekly HCQ PrEP is safe and effective in preventing COVID- 18 Although the cohort studies have limitations in terms of retrospective design and subject homogeneity, they suggest that HCQ PrEP could serve as a stop-gap approach to COVID-19 prevention until universal vaccination is achieved. Further randomized trials of HCQ PrEP should be conducted to evaluate this promising method of prevention for COVID-19 and future pandemics. The authors have no conflicts of interest to declare. There was no funding for the study. Flattening the risk: Pre-exposure prophylaxis for COVID-19. Infect Drug Resist Prospects for a safe COVID-19 vaccine Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants Indian Council of Medical Research National Taskforce for COVID-19. Advisory on the use of Hydroxychloroquine as prophylaxis for SARS CoV2 infection Healthcare workers and SARS-CoV-2 infection in India: a case-control investigation in the time of COVID-19 Pre exposure hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers Prevalence and clinical correlates of COVID-19 outbreak among health care workers in a tertiary level hospital in Delhi Seroprevalence of COVID-19 amongst health care workers in a tertiary care hospital of a metropolitan city from India. J Assoc COVID-19 infection Hydroxychloroquine pre-exposure prophylaxis for COVID-19 among healthcare workers: Initial experience from India Risk factors and frequency of COVID-19 among healthcare workers at a tertiary care centre in India: a case-control study Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 in health-care workers: A single-center experience No role of HCQ in COVID-19 prophylaxis: A survey amongst Indian doctors Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study Hydroxychloroquine for SARS CoV2 prophylaxis in healthcare workers -A multicentric cohort study assessing effectiveness and safety Safety of hydroxychloroquine among outpatient clinical trial participants for COVID-19 Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study Response to: A living WHO guideline on drugs to prevent COVID-19 The authors thank Dr. Harvey Risch and Peter Shabe for help with statistical analysis.J o u r n a l P r e -p r o o f